V. As a result of its versatility, customers can attach any kind of
molecular label to ULS and then bind the labeled ULS complex to the
biomolecules of interest. "While the
Online/Information Business was important to Celera Genomics in its
initial years, it is no longer strategically relevant and has been a
source of cash consumption, estimated to be approximately $7 million
for fiscal 2005 , since many of the subscriptions were prepaid."
"Celera Genomics now has three important strategic assets.
The Applied Biosystems Group (NYSE:ABI) serves the life science
industry and research community by developing and marketing
instrument-based systems, consumables, software, and services .

dogma mistakes

"With the anticipated discontinuation of the
Online/Information Business, Celera Genomics is now in a position to
focus its efforts on its most substantial opportunities while managing
its use of cash.
Applied Biosystems, Celera, Celera Diagnostics, Celera Discovery
System, and Celera Genomics are trademarks of Applera Corporation or
its subsidiaries in the U.

biochemistry signaling

"Geospiza's proven expertise in sequencing data management
and analysis automation provides an ideal complement to Applied
Biosystems ' industry-leading instruments, reagents, and software. With
customers ranging from academic laboratories to Fortune 50
pharmaceutical companies, Applied Biosystems' Services and System
Solutions Division supports more than 1,000 laboratories worldwide
with project management, workflow definition, application
configuration, third-party product integration, and custom software
development., Austin, Texas , US. More information on KREATECH can be accessed at
http://www.

nucleic atpases

7 billion during fiscal 2004.

In addition there will be a biotin labeling
system which is specially suited for use with Affymetrix's GeneChips(R)
Brent Keller, acting Commercial Director for KREATECH states "By
providing researchers with a total and complete system of RNA amplification
and aRNA labeling in one kit, we have enabled researchers to generate and
label their aRNA with the label of their choice., a private company founded in 1990, focuses
on the creation, development, production and marketing of innovative
diagnostic and life science products.
Finally, Celera Diagnostics, a 50-50 joint venture with Applied
Biosystems, is generating substantial product sales and making
important discoveries for incorporation into future new products," Ms
Ordonez added.
This compound is partnered with Merck , and has been in clinical trials
since July 2004. It is also seeking
to advance therapeutic antibody and selected small molecule drug
programs in collaboration with global technology and market leaders .com

Forward-Looking Statements

Certain statements in this press release are forward-looking .

howlers signaling

Geospiza Finch Suite software
system increases productivity and efficiency of sequencing labs by
integrating and automating sequencing workflows. KREATECH currently commercializes labeling kits for
aRNA labeling and arrayCGH labeling.

Business Editors/Health/Medical Writers
BIOWIRE2K

ROCKVILLE, Md.----

Filing of First Unpartnered Compound Signifies Celera's Transformation
From Selling Data to Focusing on the Realization of Downstream Value
in Targeted Medicine

Celera Genomics (NYSE:CRA), an Applera Corporation business, today
announced that it has submitted an Investigational New Drug (IND)
application to the U.
HDAC inhibitors target HDAC enzymes and inhibit the proliferation
of cancer cells and induce cancer cell death, or apoptosis(1).

carbohydrates apoptosis

Many of Geospiza's more than 10,000 customers worldwide are
already using Applied Biosystems instruments in their labs.com/

About Geospiza

Founded in 1997, Geospiza combines deep IT and life science
expertise to deliver scientifically-sound systems for managing the
production, analysis and distribution of DNA sequencing data. The Finch Suite platform provides these customers with
increased productivity, greater efficiency and more cost-effective
delivery of the data used by their customers for genomics, DNA
sequencing, genotyping, EST analysis, expression analysis and
proteomics projects . These kits are all platform independent, further increasing
the flexibility of the system by allowing the researcher to choose the array
platform of their choice."
Celera Genomics has another compound , a Cathepsin K inhibitor, in
a Phase I clinical trial as a potential treatment for osteoporosis.

Customers use these tools to analyze nucleic acids (DNA and RNA),
small molecules, and proteins to make scientific discoveries, develop
new pharmaceuticals, and conduct standardized testing.celera .
These may be identified by the use of forward-looking words or phrases
such as "believe," "expect ," "intend," "should," and "planned," among
others. All Rights Reserved.

subsets lipids

+ SEATTLE----

Joint Development Work to Deliver End-to-End Solution Linking Lab
Instruments and Integrated Samples to Final Results
in One Cohesive System

Applied Biosystems (NYSE:ABI), an Applera Corporation business,
and Geospiza, a leading developer of software for managing the
production, analysis, and distribution of DNA sequencing information,
today announced a joint collaboration agreement to develop and market
a joint informatics platform that is expected to dramatically improve
productivity and enable greater connectivity between multiple
instruments and data sources within life science laboratories.
The two businesses have begun work on creating a unique and
flexible platform that integrates Applied Biosystems' LS*LIMS(TM)
Software with Geospiza's Finch Suite.D.

Information about Applera Corporation, including reports and
other information filed by the company with the Securities and
Exchange Commission, is available at http://www.
About KREATECH
KREATECH Biotechnology B.com, or by telephoning
800. These forward-looking statements are based on Applera
Corporation's current expectations. Nature Reviews Drug Discovery, 2002,
1:287-299 .

subsets rasmol

com, or by
telephoning 800-762-6923. All information
in this press release is as of the date of the release, and Applera
does not undertake any duty to update this information, including any
forward -looking statements, unless required by law. In this
way, ULS acts as relatively simple "molecular glue" for DNA, RNA and
proteins.com
About Ambion Inc.
Ambion, The RNA Company, is a leader in the development and supply of
innovative, RNA-based life science research and molecular diagnostic
products, including the rapidly growing areas of RNAi and gene expression
array analysis . Celera Genomics published the first three-dimensional
structure of an HDAC enzyme in July 2004, and this information has
been used to aid the design of a series of novel HDAC inhibitors. Secondly ,
and with today's achievement of filing for an IND with the FDA, our
small molecule capability and pipeline of compounds is now
sufficiently mature to look to partner and capitalize on this asset . This followed a multi-year collaboration with Merck
to develop small molecule inhibitors of Cathepsin K, which was
initiated in November 1996.

recombination acids

The Applied Biosystems Group serves the life
science industry and research community by developing and marketing
instrument-based systems, consumables , software, and services.kreatech. Food and Drug Administration (FDA) for
CRA-024781, a novel histone deacetylase (HDAC) inhibitor. and/or certain other countries.

wellesley biochemistry

Applied Biosystems and Geospiza Announce Collaboration to Build Distribute and Deploy Life Science Laboratory Management Solutions

We
believe that this collaboration will benefit the scientific community
by streamlining lab productivity and increasing the ability to
consistently and cost-effectively produce, analyze, and deliver
meaningful scientific results.
"SeqWright is excited to be among the first companies to take
advantage of this impressive LIMS architecture which promises to
enhance our operational excellence and build value for our customers,"
said Kenneth Paynter, Operations Manager at SeqWright. Celera Diagnostics , a 50/50
joint venture between Applied Biosystems and Celera Genomics, is
focused on discovery , development, and commercialization of diagnostic
products. and/or certain other
countries. Under the terms of the
agreement KREATECH will utilize Ambion's MessageAmp(TM) II aRNA amplification
system in conjunction with KREATECH's proprietary Universal Linkage system
(ULS) labeling technology, to provide a series of complete RNA amplification
and labeling kits for gene expression analysis. We have allowed the
researcher the maximum flexibility while at the same time ensuring
consistent , high levels of quality and control over their amplification and
labeling system. Celera
Genomics recently reported data at the American Association for Cancer
Research (AACR) meeting in April 2005 , showing the efficacy of
CRA-024781 as an HDAC inhibitor in xenograft cancer models. In
addition , it was demonstrated that the measurement of tubulin and
histone acetylation can be used to monitor the pharmacodynamic effects
of CRA-024781 in vivo.D. Celera Diagnostics, a 50/50 joint
venture between Applied Biosystems and Celera Genomics, is focused on
discovery, development, and commercialization of diagnostic products.

prokaryotes lipids

Customers use these tools to analyze nucleic acids (DNA and RNA),
small molecules, and proteins to make scientific discoveries, develop
new pharmaceuticals, and conduct standardized testing. It is also seeking to advance therapeutic
antibody and selected small molecule drug programs in collaboration
with global technology and market leaders.S.

signaling rasmol

"Working with
Applied Biosystems and Geospiza to create more efficient and
integrated research and development capabilities gives us a decided
advantage that allows us to better serve our worldwide network of
client researchers and organizations.applera. In order to comply with the terms of the safe harbor,
Applera Corporation notes that a variety of factors could cause actual
results and experience to differ materially from the anticipated
results or other expectations expressed in such forward-looking
statements. Inhibition of these enzymes causes changes to chromatin
structure and to gene expression patterns, which results in the
inhibition of proliferation of cancer cells, and induction of
apoptosis.

rasmol alberts

Celera Genomics is
leveraging its proteomic, bioinformatic, and genomic capabilities to
identify and validate drug targets, and to discover and develop small
molecule therapeutics. Agreement Combines the Ambion MessageAmp II RNA Amplification System With
KREATECH's Universal Linkage System (ULS) Labeling Technology for Gene
Expression Applications

AMSTERDAM, the Netherlands, KREATECH
Biotechnology B. A variety of fluorescent dyes will be offered in the kits
including dyes from GE Healthcare/Amersham (CyDyes), Perkin Elmer (Cyanine
Dyes) and Dyomics (DY Dyes).
Histone deacetylation is carried out by a family of related HDAC
enzymes.6923.

carbohydrates proteomics

As part of the collaboration, Applied Biosystems will
also become a worldwide reseller of Geospiza's Finch System software
to help bring increased productivity to Applied Biosystems' customers
worldwide.

"We
anticipate that we will utilize the insights we have gained from the
identification of potential biomarkers of efficacy to design and
implement our clinical trials, the first of which is planned to assess
the safety and pharmacokinetics of CRA-024781 in a dose escalation
study, at a projected cost of less than $3 million.

rasmol recombination

"

About Applera Corporation and Applied Biosystems

Applied Biosystems is part of Applera Corporation , which consists
of two operating groups.
"We're pleased with the progress we've made in advancing
CRA-024781 through its preclinical experiments to this point," said
Robert Booth, Ph.

biochemical chime

The integrated
platform is expected to give research laboratories the ability to
create streamlined solutions for the increasingly complex challenges
associated with producing, storing, and analyzing large volumes of DNA
sequence data. The company's quality policies
are demonstrated by the implementation of ISO 9001 (2000) and ISO 13485 (GMP
2003) guidelines. Ambion has taken a leadership role in developing products for
handling, preserving, isolating, detecting amplifying and measuring RNA in
areas such as molecular biology, cell biology, microbiology, drug discovery
and genomics.applera.

This category includes resources for the teaching and learning of biochemistry as a whole, for teachers, students and the general public.

proteomics biochemistry

"
Applied Biosystems' instruments, including the 3130 Series Genetic
Analyzers and 3730 Series DNA Analyzers, are currently compatible with
both the enterprise and laboratory versions of Geospiza Finch Suite
software.com

Applied Biosystems Forward Looking Statements

Certain statements in this press release are forward-looking.

Celera Genomics Files Investigational New Drug Application for Novel HDAC Inhibitor CRA-024781

Celera Genomics is leveraging its proteomic, bioinformatic ,
and genomic capabilities to identify and validate drug targets, and to
discover and develop small molecule therapeutics.7 billion during fiscal 2004. All
information in this press release is as of the date of the release,
and Applera does not undertake any duty to update this information,
including any forward-looking statements, unless required by law.

nucleic howlers

"
Early access customers, such as SeqWright, a DNA technologies
services lab, have already implemented the integrated platform from
Applied Biosystems and Geospiza. Information about Applied Biosystems is
available at http://www .S."
KREATECH's ULS technology relies on the special binding properties of
transition metals , especially platinum, to form coordinative bonds with
biomolecules by binding to specific sites on DNA, RNA and proteins. KREATECH's proprietary Universal
Linkage System (ULS(TM)) offers a reliable , robust and easy to use
non-enzymatic technology that can be applied to a broad range of biomolecules
and labeling agents. In order to comply with the terms of the safe harbor,
Applera Corporation notes that a variety of factors could cause actual
results and experience to differ materially from the anticipated
results or other expectations expressed in such forward-looking
statements.

signaling apoptosis

KREATECH Biotechnology B.V. Signs Technology Supply Agreement With Ambion Inc.

chime nucleic

,
chairman and CEO at Geospiza.

Applied Biosystems and Celera are registered trademark and
LS*LIMS, Applera, Celera Diagnostics are trademarks of Applera
Corporation or its subsidiaries in the U."
"Today's accomplishment reflects Celera's successful transition
from sequencing the human genome and selling data to focusing on the
realization of downstream value in therapeutics and diagnostics," said
Kathy Ordonez, President of Celera Genomics. Applied
Biosystems is headquartered in Foster City, CA, and reported sales of
$1. Information about Celera Genomics is available at
www . Applera Corporation. Histone-Deactylase Inhibitors: Novel drugs for
the treatment of cancer.

genomics acids

More information is available at
www.geospiza. The risks and uncertainties that may affect the
operations , performance, development, and results of Applied
Biosystems include but are not limited to: (1) rapidly changing
technology could adversely affect demand for Applied Biosystems'
products, and its business is dependent on development of new
products; (2) dependence on continuous, effective , reliable, and
secure operation of its computer hardware, software, and Internet
applications and related tools and functions; and (3) other factors
that might be described from time to time in Applera Corporation's
filings with the Securities and Exchange Commission., Chief Scientific Officer of Celera Genomics.

carbohydrates lipids

Business Editors/Biotech Writers
BIOWIRE2K

FOSTER CITY, Calif.

Applied
Biosystems is headquartered in Foster City, CA, and reported sales of
$1. This kit will provide users
with all the reagents necessary to go from total RNA samples to microarrays
in one box. First,
our proteomics platform continues to yield novel cancer targets that
have been the focus of several partnerships for drug discovery and
development, allowing us to advance them cost effectively.762.

univ molecular

"By deepening the integration between
the Geospiza Finch Suite platform and a wide array of Applied
Biosystems' technologies both small labs and large enterprise-size
core facilities can, for perhaps the first time, invest in a cohesive,
data generation, analysis, and management system that can grow with
them as their needs grow. The Celera Genomics Group is engaged
principally in the discovery and development of targeted therapeutics
for cancer, autoimmune and inflammatory diseases. Pending
clearance by the FDA, Celera Genomics plans to initiate Phase 1
clinical trials .
Information about Applera Corporation, including reports and other
information filed by the company with the Securities and Exchange
Commission, is available at www. The Private Securities Litigation
Reform Act of 1995 provides a "safe harbor" for such forward-looking
statements.

wellesley molecular

"Central to our integrated science philosophy is delivering
innovative solutions that create better linkages between biological
data and laboratory research," said Michael Schneider, Division
President, Service and System Solutions Division for Applied
Biosystems.
"Our collaboration with Applied Biosystems should bring
significant productivity gains to sequencing and genomic labs for both
research and pre-clinical applications," noted Todd Smith, Ph.
These may be identified by the use of forward -looking words or phrases
such as "believe," "expect," "should," "anticipate," and "planned,"
among others. These forward-looking statements are based on Applera
Corporation's current expectations . The Private Securities Litigation
Reform Act of 1995 provides a "safe harbor" for such forward-looking
statements. KREATECH is committed to achieve and maintain the
highest standards in production and quality control as well as in the
relationships with our customers and partners.S.

About Celera Genomics and Applera Corporation

Applera Corporation consists of two operating groups . The Celera
Genomics Group is engaged principally in the discovery and development
of targeted therapeutics for cancer, autoimmune and inflammatory
diseases. These risks and uncertainties include but are not limited
to: (1) Celera Genomics' unproven ability to discover, develop, or
commercialize proprietary therapeutic products; (2) the risk that
clinical trials of products that Celera Genomics does discover and
develop will not proceed as anticipated or may not be successful, or
that such products will not receive required regulatory clearances or
approvals; (3) the uncertainty that Celera Genomics' products will be
accepted and adopted by the market, including the risk that that these
products will not be competitive with products offered by other
companies, or that users will not be entitled to receive adequate
reimbursement for these products from third party payors such as
private insurance companies and government insurance plans; (4)
uncertainty of the availability to Celera Genomics of intellectual
property protection, limitations on their ability to protect trade
secrets, and the risk to them of infringement claims; and (5) other
factors that might be described from time to time in Applera
Corporation's filings with the Securities and Exchange Commission.

(1)Johnstone, RW.

carbohydrates nucleic

appliedbiosystems. The
company's primary customers are core facilities and research
laboratories in commercial, education, government and non-profit
settings. All other trademarks are the sole property of their
respective owners. is pleased to announce the signing of a Technology Supply
Agreement with Ambion Inc.